Journal of women's health
-
Journal of women's health · May 2022
Factors Associated with Vaginal Lactobacillus Predominance Among African American Women Early in Pregnancy.
Background: Vaginal Lactobacillus is considered protective of some adverse reproductive health outcomes, including preterm birth. However, factors that increase or decrease the likelihood of harboring Lactobacillus in the vaginal microbiome remain largely unknown. In this study, we sought to identify risk and protective factors associated with vaginal Lactobacillus predominance within a cohort of pregnant African American women. ⋯ Lactobacillus iners) predominance (aOR 1.11, 95% CI 0.52-2.38 and aOR 0.56, 95% CI 0.21-1.47, respectively). Conclusions: Living with a partner is conducive to vaginal Lactobacillus predominance. As such, cohabitation may be in important covariate to consider in vaginal microbiome studies.
-
Journal of women's health · May 2022
Vision 2020: How Caregiving and Work Productivity Outlook Shifted for Academic Pediatric Faculty.
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected both home and work routines and may have exacerbated existing inequities. The objectives of this study were to describe pediatric faculty work productivity and caregiving responsibilities during the pandemic, identify groups at risk, and better understand mitigation strategy preferences. Materials and Methods: We conducted a cross-sectional electronic survey of Department of Pediatric faculty. ⋯ Wellness concerns by faculty could affect work performance. Researchers report a worse 1-year outlook than the other groups. Faculty identified preferred strategies to potentially assist in maintaining their productivity.
-
Journal of women's health · May 2022
ReviewDoes Journal Content in the Field of Women's Health Represent Women's Burden of Disease? A Review of Publications in 2010 and 2020.
Background: Historically, women's health has focused on reproductive health. However, noncommunicable and communicable diseases comprise much of the burden of disease in women. Methods: A quantitative analysis of the main health content of articles published in six women's health journals (WHJ) and five general medical journals (GMJ) in 2010 and 2020 was conducted to categorize the main medical area topics of published articles and the life stage under study. ⋯ Most articles that focused on a particular life stage were on pregnancy or the reproductive years, with very few articles on menopause. Conclusion: Women's health publishing remains largely focused on reproductive health topics, with few articles on many of the major causes of morbidity and mortality in women. Journals, researchers, funders, and research priority setters should embrace a broader view of women's health to effectively cover content that reflects the broad range of health issues impacting women across the life span.
-
Journal of women's health · May 2022
Multicenter StudyTrends in Bacterial Vaginosis Prevalence in a Cohort of U.S. Women with and at Risk for HIV.
Background: Women with human immunodeficiency virus (HIV) often have bacterial vaginosis (BV). The goal of this analysis was to assess how BV prevalence changed over time and across U. S. regions in enrollment cohorts of the Women's Interagency HIV Study. ⋯ Prevalence varied across sites, but was not uniformly increased or decreased in any U. S. region. Clinical Trials.gov identifier: NCT00000797.
-
Journal of women's health · May 2022
Randomized Controlled TrialReduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily) or placebo who were not considered responders in pooled analysis of two phase 3, 6-month randomized clinical trials (Elaris UF-1 and UF-2). Methods: Responders were defined as women who met both primary end point bleeding criteria (<80 mL menstrual blood loss [MBL] during the final month and ≥50% reduction in MBL from baseline to the final month) and either completed the study or discontinued due to predefined reasons. Thus, women termed nonresponders who were analyzed in this study who met neither or one bleeding end point or met both criteria but prematurely discontinued treatment because of adverse events, perceived lack of efficacy, or required surgical or interventional treatment for UFs were analyzed in this study. ⋯ No differences in adverse events were observed between responders and nonresponders. Conclusion: Forty of 89 (45%) women with HMB and UFs who were classified as nonresponders in the UF-1 or UF-2 trials may have had a clinically meaningful response to elagolix with add-back therapy because they met at least one of the objective bleeding criteria. Clinical Trial Registration: Clinicaltrials.gov, NCT02654054 and NCT02691494. (NEJM 2020; 382:328-340) DOI: 10.1056/NEJMoa1904351.